Eli Lilly’s once-weekly insulin, Onswik (efsitora alfa), has cleared an important hurdle toward UK use: England’s cost-effectiveness watchdog NICE has recommended it for the NHS — pending final marketing authorization.
The appeal is simple: a single weekly injection instead of a daily one. Onswik would cut injection frequency by roughly 85%, which NICE highlighted as especially valuable for patients who find daily insulin hard to manage — older people, those with limited hand mobility, and people who need help injecting. “Moving from daily injections to a single weekly dose could make a real difference to the day-to-day lives” of eligible patients, said NICE’s Helen Knight.
The evidence
The recommendation rests on Lilly’s Phase 3 QWINT program, in which Onswik delivered blood-sugar control equivalent to widely used daily long-acting insulins (insulin degludec and insulin glargine). The initial NHS use targets type 2 diabetes.
Where it stands
NICE issued its positive recommendation in August 2026, following a positive opinion from the European Medicines Agency’s CHMP in June 2026; UK marketing authorization from the MHRA is expected. Weekly insulins are a closely watched category — if uptake follows, they could simplify treatment for millions and reshape a cornerstone of diabetes care.